Biolegend, 100729, Alexa Fluor® 700 anti-mouse CD8a Antibody, 25μg

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses
Excitation Laser: Red Laser (633 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed Roussel-Queval A, et al. 2023. STAR Protoc. 4:102119. PubMed Li X, et al. 2023. J Clin Invest. 133:. PubMed Falahat R, et al. 2023. Nat Commun. 14:1573. PubMed Comeau K, et al. 2023. Bio Protoc. 13:e4679. PubMed Wang Y, et al. 2021. Cancer Res. 81:174. PubMed Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed Abdelnabi MN, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:1269. PubMed Ostendorf BN, et al. 2022. Nature. 611:346. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Edwards CL, et al. 2023. J Clin Invest. 133: . PubMed Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed Merk VM, et al. 2023. Genes Immun. 24:52. PubMed Cui B, et al. 2023. Int Immunopharmacol. 114:109541. PubMed Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed Fan L, et al. 2021. Cancers (Basel). 13:. PubMed Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed Zhang YS, et al. 2018. Cancer Biol Ther. 19:735. PubMed Chen J, et al. 2021. Sci Adv. 7:. PubMed Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed Gruber T, et al. 2020. JCI Insight. 5:00. PubMed Annu K, et al. 2020. Sci Rep. 10:2359. PubMed Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed Liu X, et al. 2021. eLife. 0.416666666666667. PubMed Qi X, et al. 2019. Nat Commun. 10:2141. PubMed Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed Ye M, et al. 2022. Nat Nanotechnol. 17:880. PubMed Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed Ma C, et al. 2016. Nature. 531:253-257. PubMed Panciera T, et al. 2016. Cell Stem Cell. 19:725-737. PubMed Nakagawa P, et al. 2017. Physiol Rep. 10.14814/phy2.13084. PubMed Biancur DE, et al. 2020. Cell Metabolism. 33(1):199-210.e8. PubMed He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed Alsaleh G, et al. 2020. Elife. 9: . PubMed Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed Wang B, et al. 2022. Nat Commun. 13:3821. PubMed Bunn P, et al. 2014. J Immunol. 192:3709. PubMed Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed Pérol L, et al. 2016. Nat Commun. 7:13027. PubMed He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed Yue X, et al. 2019. Nat Commun. 10:2011. PubMed Wang F, et al. 2018. Carcinogenesis. 39:889. PubMed Kim C, et al. 2019. Cell Rep. 29:2202. PubMed Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed Panea C, et al. 2021. Commun Biol. 4:913. PubMed Carty S, et al. 2014. PLoS One. 9:106659. PubMed Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed Zhang H, et al. 2019. Mol Cell. 76:110. PubMed Yang Y, et al. 2021. Sci Adv. 7:eabf6290. PubMed Sobecki M, et al. 2021. Nat Commun. 12:4700. PubMed Solaymani-Mohammadi S, et al. 2016. J Leukoc Biol. 99: 475 - 482. PubMed Qiao J, et al. 2019. Cancer Cell. 35:901. PubMed Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed Zhu X et al. 2019. Cell reports. 27(4):1205-1220 . PubMed Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed Bronisz–Budzynska I, et al. 2019. Skelet Muscle. 9:22. PubMed Chen RJ, et al. 2022. iScience. 25:105595. PubMed Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed Engel I, et al. 2016. Nat Immunol. 10.1038/ni.3437. PubMed Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed Li C, et al. 2018. Cell. 174:285. PubMed Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed Li N, et al. 2022. Nat Commun. 13:7281. PubMed Georgiadou A, et al. 2022. Elife. 11:. PubMed McPhee C, et al. 2013. J Immunol. 191:4581. PubMed Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed Yoshida H, et al. 2019. Cell. 176:897. PubMed Yan C, et al. 2022. NPJ Precis Oncol. 6:6. PubMed Zhang Z, et al. 2020. Nature. 579:415. PubMed Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed Fite BZ, et al. 2021. Sci Rep. 11:927. PubMed Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed Hall JA, et al. 2020. Cell Metabolism. 32(4):665-675.e6. PubMed Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed Gawish R, et al. 2022. Elife. 11:. PubMed Engelbertsen D, et al. 2013. Arterioscler Thromb Vasc Biol. 33:637. PubMed
RRID: AB_493702 (BioLegend Cat. No. 100729) AB_493703 (BioLegend Cat. No. 100730)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ